ARO-ANG3

Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic disorder causing high LDL-C levels, leading to early cardiovascular disease. The market, valued at USD 108 million in 2022, is expected to grow significantly by 2034. Key companies include Arrowhead Pharmaceutical and Novartis, with therapies like ARO-ANG3 and LEQVIO. The US had 1,349 HoFH cases in 2022, projected to increase. Treatments include statins, PCSK9 inhibitors, and novel therapies like evinacumab, approved for children as young as 5.

The Homozygous Familial Hypercholesterolemia (HoFH) market, valued at USD 108 million in 2022, is expected to grow significantly by 2034. Key companies like Novartis and Sanofi are developing therapies such as ARO-ANG3 and Evinacumab. HoFH, a rare genetic disorder causing high LDL-C levels, requires aggressive treatment to prevent early cardiovascular disease.

Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic disorder causing high LDL-C levels, leading to early cardiovascular disease. The market, valued at USD 108 million in 2022, is expected to grow significantly by 2034. Key companies like Novartis and Arrowhead Pharmaceutical are developing therapies such as ARO-ANG3 and LEQVIO. The FDA approved Evkeeza for children with HoFH, marking a significant advancement. Early detection and aggressive treatment are crucial for managing HoFH.

DelveInsight's report on Homozygous Familial Hypercholesterolemia (HoFH) forecasts market growth, driven by increasing prevalence and new therapies. The 7MM saw 2,845 HoFH cases in 2022, expected to rise by 2034. Key companies like Novartis and Sanofi are developing treatments targeting LDL-C reduction, with the market valued at USD 108 million in 2022.